Improved Identification and Antihypertension Pharmacotherapy in Cardiorenal Metabolic Syndrome: Focus on Racial/Ethnic Minorities, Olmesartan Medoxomil, and Combination Therapy

Publisher： Karger

E-ISSN： 1664-5502|2|4|256-267

ISSN： 1664-3828

Source： Cardiorenal Medicine, Vol.2, Iss.4, 2012-10, pp. : 256-267

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cardiorenal Metabolic Syndrome and Diabetic Cognopathy

By  

Cardiorenal Medicine, Vol. 3, Iss. 4, 2013-11 ,pp. : 265-282

Karger

Access to resources Recommend Favorite

Mitochondria and Oxidative Stress in the Cardiorenal Metabolic Syndrome

By  

Cardiorenal Medicine, Vol. 2, Iss. 2, 2012-02 ,pp. : 87-109

Karger

Access to resources Recommend Favorite

Cardiorenal Metabolic Syndrome and Cardiometabolic Risks in Minority Populations

By  

Cardiorenal Medicine, Vol. 4, Iss. 1, 2013-12 ,pp. : 1-11

Karger

Access to resources Recommend Favorite

Uric Acid - Key Ingredient in the Recipe for Cardiorenal Metabolic Syndrome

By  

Cardiorenal Medicine, Vol. 3, Iss. 3, 2013-01 ,pp. : 208-220

Karger

Access to resources Recommend Favorite

Gestational Diabetes and the Offspring: Implications in the Development of the Cardiorenal Metabolic Syndrome in Offspring

By  

Cardiorenal Medicine, Vol. 2, Iss. 2, 2012-04 ,pp. : 134-142

Karger

Access to resources Recommend Favorite